TMPRSS2 and prostate carcinoma: Since increased expression of TMPRSS2 stimulates androgen-driven prostate cancer progression, therapeutic approaches directed toward inhibition of TMPRSS2 have been suggested to reduce the risk of metastatic progression in patients with prostate cancer [54].